370 related articles for article (PubMed ID: 11242145)
1. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Polli JW; Jarrett JL; Studenberg SD; Humphreys JE; Dennis SW; Brouwer KR; Woolley JL
Pharm Res; 1999 Aug; 16(8):1206-12. PubMed ID: 10468021
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
4. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
5. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation.
Megard I; Garrigues A; Orlowski S; Jorajuria S; Clayette P; Ezan E; Mabondzo A
Brain Res; 2002 Feb; 927(2):153-67. PubMed ID: 11821009
[TBL] [Abstract][Full Text] [Related]
6. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
7. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants.
Cox DS; Scott KR; Gao H; Raje S; Eddington ND
J Pharm Sci; 2001 Oct; 90(10):1540-52. PubMed ID: 11745712
[TBL] [Abstract][Full Text] [Related]
8. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.
van der Sandt IC; Smolders R; Nabulsi L; Zuideveld KP; de Boer AG; Breimer DD
Eur J Pharm Sci; 2001 Aug; 14(1):81-6. PubMed ID: 11457654
[TBL] [Abstract][Full Text] [Related]
9. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3).
Florea BI; van der Sandt IC; Schrier SM; Kooiman K; Deryckere K; de Boer AG; Junginger HE; Borchard G
Br J Pharmacol; 2001 Dec; 134(7):1555-63. PubMed ID: 11724763
[TBL] [Abstract][Full Text] [Related]
10. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Ronaldson PT; Lee G; Dallas S; Bendayan R
Pharm Res; 2004 May; 21(5):811-8. PubMed ID: 15180339
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH
AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
13. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
14. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
15. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
Drewe J; Gutmann H; Fricker G; Török M; Beglinger C; Huwyler J
Biochem Pharmacol; 1999 May; 57(10):1147-52. PubMed ID: 11230802
[TBL] [Abstract][Full Text] [Related]
16. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).
Olson DP; Scadden DT; D'Aquila RT; De Pasquale MP
AIDS; 2002 Sep; 16(13):1743-7. PubMed ID: 12218384
[TBL] [Abstract][Full Text] [Related]
17. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
[TBL] [Abstract][Full Text] [Related]
18. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone.
Karssen AM; Meijer OC; van der Sandt IC; De Boer AG; De Lange EC; De Kloet ER
J Endocrinol; 2002 Oct; 175(1):251-60. PubMed ID: 12379510
[TBL] [Abstract][Full Text] [Related]
19. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.
Bachmeier CJ; Spitzenberger TJ; Elmquist WF; Miller DW
Pharm Res; 2005 Aug; 22(8):1259-68. PubMed ID: 16078135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]